RecruitingNCT06346405

Central Serous Chorioretinopathy and Micropulse Laser Treatment

Central Serous Chorioretinopathy and Micropulse Laser Treatment: Evaluation of Morphological and Functional Recovery

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

36 participants

Start Date

May 31, 2023

Study Type

OBSERVATIONAL

Conditions

Central Serous Chorioretinopathy

Summary

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
Foveal serous retinal detachment for at least 6 months.
Minimum age of 18 years old at the screening time
Reading and comprehension skills of informed consent

Exclusion Criteria9

Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
No diffuse retinal epitheliopathy
Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
Not controlled glaucoma with eyedrops, or advanced glaucoma
Myopia or hypermetropia greater than 6 diopters
Opacities of dioptric media
Low quality of optical coherence tomography (OCT) and OCT-Angiography scans
Low quality images of Fluorescein angiography and indocyanine green angiography
No written consensus signed.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSubthreshold Micropulse Laser Treatment

Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.